This Article Full Text Full Text (PDF) All Versions of this Article: 38/8/2215    most recent STROKEAHA.107.494112v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Demaerschalk, B. M. Search for Related Content PubMed PubMed Citation Articles by Demaerschalk, B. M. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Stroke Related Collections Acute Cerebral Hemorrhage Acute Cerebral Infarction Emergency treatment of Stroke Thrombolysis Related Article

(Stroke. 2007;38:2215.)
© 2007 American Heart Association, Inc.

Editorials

Thrombolytic Therapy for Acute Ischemic Stroke

The Likelihood of Being Helped Versus Harmed

Bart M. Demaerschalk, MD, MSc, FRCP(C)

From the Division of Cerebrovascular Diseases, Division of Critical Care Neurology, Department of Neurology, Mayo Clinic Hospital, Mayo Clinic College of Medicine, Phoenix, Ariz.

Correspondence to Bart M. Demaerschalk, Division of Cerebrovascular Diseases, Division of Critical Care Neurology, Department of Neurology, Mayo Clinic Hospital, Mayo Clinic College of Medicine, 5777 East Mayo Blvd, Phoenix, AZ 85054. E-mail demaerschalk.bart@mayo.edu

An extract of the first 250 words of the full text is provided, because this article has no abstract.

See related article, pages 2279–2283.

Symptomatic intracerebral hemorrhage (SICH) risk is the factor most likely to preclude tissue plasminogen activator (tPA) use by emergency physicians. Of the 40% of respondents to the American College of Emergency Physicians survey about tPA for acute ischemic stroke who would not use tPA in the ideal setting reported that this was attributable to SICH risk.¹ From the same survey, we learned that in the respondents’ minds, the highest clinically acceptable mean risk of SICH was 3.4% (compared with 6.4% risk reported in the tPA arm of the National Institute of Neurological Disorders and Stroke [NINDS] trial).

The American Academy of Emergency Medicine (AAEM) has created an educational tool entitled "tPA for Stroke—Potential Benefit, Risk, and Alternatives," dated May 3, 2007, that was circulated to its membership.² The document was designed to help emergency physicians inform patients and family members about the pros and cons of tPA for stroke in appropriate patients. The tool emphasizes how important it is for physicians to weigh the possibility of benefit (improved function at 3 months) against the possibility of harm (severe bleeding or death). The AAEM has produced an accompanying illustration to pictorially and quantitatively convey the probabilities of "good recovery," "poor or no recovery," and "brain bleed and death" with and without tPA in cohort of acute ischemic stroke patients. In reviewing the potential benefit, the illustration suggests that 8 of 18 stroke patients who receive tPA will have a good recovery by 3 months . . . [Full Text of this Article]

Related Article:

Hemorrhage After Thrombolytic Therapy for Stroke: The Clinically Relevant Number Needed to Harm

Jeffrey L. Saver
Stroke 2007 38: 2279-2283. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

				G. J. del Zoppo, J. L. Saver, E. C. Jauch, H. P. Adams, and On behalf of the American Heart Association Stroke Response to Letters by Asimos and by Alper and Brown Stroke, November 1, 2009; 40(11): e634 - e635. [Full Text] [PDF]

				J. L. Saver, J. Gornbein, J. Grotta, D. Liebeskind, H. Lutsep, L. Schwamm, P. Scott, and S. Starkman Number Needed to Treat to Benefit and to Harm for Intravenous Tissue Plasminogen Activator Therapy in the 3- to 4.5-Hour Window: Joint Outcome Table Analysis of the ECASS 3 Trial Stroke, July 1, 2009; 40(7): 2433 - 2437. [Abstract] [Full Text] [PDF]

				B. A. Liang, R. Lew, and J. A. Zivin Review of Tissue Plasminogen Activator, Ischemic Stroke, and Potential Legal Issues Arch Neurol, November 1, 2008; 65(11): 1429 - 1433. [Abstract] [Full Text] [PDF]